搜索
请登录
提醒成功
微信/QQ登录
搜索
首页
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00045 |
| Application | Flow cytometry, animal model study |
| Aliases | B29, IGB, Ig-beta |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human CD79B |
| Formulation | PBS, pH 7.4 |
Description |
|---|
What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab. |
Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody B00045
规格：
- 1mg
- 5mg
- 20mg
数量：
-
+
说明书：
¥2275
-
分享
-
咨询
-
收藏
联系方式
CONTACT-
联系电话:
0731-88388787 -
公司邮箱:
sales@promab.cn -
公司地址:
湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼
官方微信
产品中心
Product技术服务
service客户留言
message